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                           PREVALENCE OF LEFT VENTRICULAR 
                               SYSTOLIC DYSFUNCTION IN  
          CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
ABSTRACT:  
Background: 
COPD is now more prevalent in both developed and developing countries. It 
is projected to be the third most common cause of death and fifth most common 
cause of chronic disability by the year 2030. In India half a million people die of 
COPD.COPD obscure the clinical signs of coexisting left ventricular dysfunction 
like cough, dyspnea, paroxysmal nocturnal dyspnea and orthopnea. Symptoms of 
dyspnea in COPD can be partially due to LV systolic and diastolic dysfunction. 
More number of patients is either under or wrongly diagnosed, that leads to 
worsening and development of complications. Early identification and treatment of 
LV dysfunction can improve the patient’s symptoms. 
Aim of the study : 
To study the prevalence of LV systolic dysfunction in COPD patients and to 
assess the possible risk factors contributing to the development of LV systolic 
dysfunction.  
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Methods and materials: 
 The study design was approved by the Ethical Committee of the institution. 
This study was done at Government Royapettah Hospital, Chennai between May 
2013 to October 2013 .This is a cross sectional study in which 50 patients with 
COPD more than 40 years of age. Severity of COPD is assessed by Spirometry. 
LVEF was measured by 2D Echo. Duration of smoking and smoking index also 
was calculated.   
 Results: 
 Among the 50 COPD patients, duration of smoking, smoking index and 
severity of COPD correlated with LVEF. .  ‘p’ value was  significant. COPD is 
more prevalent in males. Most patients belong to low socio economic status. 
COPD severity is directly proportional to smoking index and duration of smoking.  
Our study reports that 10% of the COPD patients have LV systolic dysfunction. A 
higher smoking index and prolonged duration of smoking is associated with poor 
LV systolic function. Increasing severity of COPD is associated with worsening of 
LV systolic function 
Conclusion: 
 LV systolic dysfunction is directly proportional to severity of COPD. 
Smoking index and duration of smoking are positively correlated with 
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development of LVSD. Routine echocardiography is recommended for all severe 
COPD patients. Smoking cessation should be a vital part of treatment plan in 
COPD patients. In COPD patients with LVSD, it may be good to introduce 
selective beta-1 blocker, diuretics, ACE inhibitors, angiotensin-II antagonist and 
aldosterone antagonist. 
Key words: 
Chronic obstructive pulmonary disease, smoking, severity of COPD, Spirometry, 
Echocardiography, LV systolic dysfunction 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a disease 
state“characterized by thepresence of airflow obstruction due to chronic bronchitis 
oremphysema; the airflow obstruction is progressive and partially 
revers ible”.COPD is now widely prevalent in both developed and developing 
countries causing major health burden to the society.  
According to “WHO” report, COPD at present is the fourth commonest 
cause of death worldwide. It is proposed to be the third major cause of mortality 
and fifth major cause of chronic disability by the year 2030.In India  every year 
half a million people die of COPD.Cigarette smoking is the key risk factor, other 
risk factors being exposure to indoor and outdoor pollution, occupationalhazards, 
infection and genetic factors. 
Most COPDpatients die of pulmonary and extra pulmonary 
complications.Pulmonary hypertension,corpulmonale and left ventricular 
dysfunction are the important cardiac predictor for mortality. 
COPD obscure the clinical signs of coexisting left ventricular dysfunction 
like cough,dyspnea, paroxysmal nocturnal dyspnea andorthopnea.More number of 
patients is either under or wrongly diagnosed,that leads to worsening and 
development of complications. 
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Routinespirometeryis used to diagnoseand to assess the severity of COPD 
and echocardiography is mandatory to assess the cardiac status in COPD patients. 
The awareness among patients regarding COPD and its complications is 
less, so more attention is needed for COPD patients pertaining to the development 
of complications. 
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REVIEW OF LITERATURE 
HISTORICAL BACKGROUND 
COPD has existed since time unknown but has been described by various 
terminologies in the past. Bonet described a condition named "voluminous lungs" 
as long back as 1679. In 1769, Giovanni Morgagniproposed lungs becoming 
"turgid"particularly from some airborne factor.[1]Ruysh provided the first authentic 
illustration and described the enlarged airspaces in emphysema in 1721.[2] 
The destructive nature of the emphysematous lung wasillustrated and 
described by Matthew Bailliein 1789.[1] In 1814 Badham denoted the word 
"catarrh" to the cough and mucus hypersecretion in patients with chronic bronchitis 
and also described it as a disabling state.Rene Laennec, the inventor of 
stethoscopedescribed “emphysema" in his book as“A Treatise on the Diseases of 
the Chest and Mediate Auscultation” (1837). 
William Briscoe in 1965 designated the term COPD.This terminology has 
overtaken other lesser popular terminologies and to become the established name 
for this disease currently. British Thoracic Society(BTS) accepted and adopted the 
COPD terminology and formulated guidelines for COPD management. 
DEFINITION: 
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American Thoracic Society (ATS) defined COPD is “a disease state 
characterized by the presence of airflow obstruction due to chronicbronchitis or 
emphysema; the airflow obstruction is generallyprogressive, may be accompanied 
by airway hyper-reactivity, and may be partially reversible.” 
OTHER NAMES FOR COPD: 
Chronic obstructive airway disease (COAD) 
Chronic obstructive lung disease (COLD) 
Chronic air flow limitation (CAL) 
CHRONIC BRONCHITIS: 
 Chronic bronchitis is defined as “the presence of chronic productive cough 
for 3 months during each of two successive years in a patient in whom other causes 
of chronic cough, such as infection with mycobacterium tuberculosis, carcinoma of 
the lung, bronchiectasis, cystic fibrosis, and chronic congestive heart failure, have 
been excluded.” 
The three forms of chronicbronchitis: 
1. Simple bronchitis: mucus hypersecretion. 
2. Chronic or recurrent mucopurulent bronchitis: intermittent or persistent 
mucopurulent sputum. 
 3. Chronic obstructive bronchitis : chronic sputumproductionalongwith airflow 
obstruction. 
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EMPHYSEMA: 
Emphysema is defined as “a condition of the lung characterized by abnormal 
permanent enlargement of the air spaces distal to the terminal bronchioles 
accompanied by destruction of their walls without obvious fibrosis.” “Destruction 
is defined as nonuniformity in the pattern of respiratory air-space enlargement; the 
orderly appearance of the acinus and its components is disturbed and may be lost.” 
CLASSIFICATION OF EMPHYSEMA 
 
PANACINAR (PANLOBULAR) EMPHYSEMA: 
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Acini are almostuniformly involved (and lobule). 
CENTRIACINAREMPHYSEMA: 
Dominant involvement of the proximal portion of the acinus (center of the 
lobule)  
PARASEPTAL EMPHYSEMA (DISTAL ACINAR) EMPHYSEMA: 
The distal part predominantly involved(alveolar ducts and sacs) and the 
proximal part relatively spared. 
IRREGULAR EMPHYSEMA (PARACICATRICIAL EMPHYSEMA): 
Acinus may be irregularly involved, usually associated with obvious 
scarring. 
BURDEN OF COPD 
EPIDEMOLOGY 
COPD currently tops the list as the major cause of morbidity and mortality 
throughout the world and contributes significantly to the economic and social 
burden globally.(4 
COPD prevalence,morbidity and mortality directly related to risk factors like 
smoking,indoor and outdoor pollution.  
The prevalence is increasing atpresent due to continuous exposure to risk 
factors.COPD prevalence is more in males than females and with advancing 
age.Increasing trend in prevalence of COPD is observed among women.Ray et alin 
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1995found that the prevalence of COPD in male was 4.08 percent and in females 
was around 2.55 percent from south India.(7) But in SEARO Region higher COPD 
prevalence was observed among women than men due to indoor air pollution 
(Pandy 1984; Behera and Jindal 1991).(9) National health interview surveyreport in 
United States in the year 2007 to 2009 shows the COPD prevalence was higher in 
older age groups, and most of the lifespan women had higher rates than 
men.NCMH estimates in India there were around 17 million COPD patients in 
2006 but it is around 22 million in the next 10 year.(11) 
 
 
 Acute exacerbation of COPD is a greatest burden. In European  countries 
direct cost of respiratory disease is 6% of total health budget, with COPD 
accounting 56% of this cost of respiratory disease(8).  
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COPD kills more than 3 million people every year worldwide.(5)At present it 
is the fourth leading cause of death, by the year 2030 it becomes third leading 
causeof death..In India half a million people die of COPD. (6)This is4 times the 
mortality that it causes in USA and Europe.(122)Nongkinryhet al published the 
WHO data of non-Communicable disease in India from 1998 to 2002 (JAPI, 
2004). Asthma and COPD were second most cause for mortality. The morbidity 
figures around 55million cases for both Asthma and COPD.(12) 
 
COPD mortality increases with age and the incidence is higher in men than 
women.(13,14,15,)Theincomplete recognition and diagnosis of COPD further 
miscalculates the prevalence, morbidity and mortality rates. Most COPD patients 
do not die of the disease per se andalsodue to accompanyingco-morbid 
conditions.(16) 
ETIOLOGY OF COPD: 
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COPD is a major health problem principally in societies where cigarette 
smoking is common and nonsmokers also develops the disease.  
 
Risk factors for the development of COPD may be broadly divided into 
those related to environmental exposure and host factors. 
 
 Smoking is the major risk factor; other risk factors are alpha 1-antitrypsin 
(α1-AT) deficiency, occupational exposure, childhood lower respiratoryinfections, 
airway hyper responsiveness, geneticfactors and low socioeconomic status.In 
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alpha1-antitrypsin deficiencysmoking exacerbatesthedevelopment ofemphysema   
indicating a clear genetic predisposition to COPD. (17)In India biomass smoke 
exposure becomesa major risk factor andburning of mosquito coils also a common 
indoor air pollutant. 
ENVIRONMENTAL 
SMOKING 
In the United States therisk of developing COPD due to tobacco smoking 
accounts for 80% to 90%. (19) FEV1 begins to decline at 30–35 years of age in non-
smokers but in smokers this may occur earlier.[22]Nonsmokers commonly have 
decline the rate FEV1 of about 30mL .Smokers on the other hand have a decline 
inFEV1 of about 50 ml. In males, the loss of FEV1 in excess of the normal decline 
with aging is 9 ml per year for each pack-year of smoking;in females, the excess 
rate of decline is 6 ml.The risk of developing COPD isgreater in tobacco 
exposures.(20) Swedish cohort study concluded that smoking was a causative risk 
factor of COPD and the attributed risk in a given population was 76.2 %(27) where 
as In Denmark study itwas 74.6 percent.(28)BTS guidelines reported that most 
COPD patients have history of at least 20 pack-year of smoking.[21]Cigarette 
smokers have a higher prevalence of chronic bronchitis. Confounding factors like 
inhaled cigarette smoke, tar, nicotine and other constituents may complicate the 
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relationship between the numbers of cigarettes smoked andrate of decline in 
FEV1.[23] 
 
Cigarette smokers had a significantly higher mortality rate compared to 
nonsmokers. Cessation of smoking does not substantially improvethe FEV1 but the 
subsequent rate of disease progression is decreased. [24,25] Indian people smoke 
tobaccoin various forms like beedis, hookahs and chillums. The chillum is the most 
harmful of the lot followed by hookahs and beedis respectively. Beedis are 
moredangerous than cigarettes (it contains only one fourth the amount of nicotine, 
but it produces four to five times more tar than cigarettes).(26) 
OCCUPATIONAL EXPOSURE: 
The effect of occupational exposures is usually small compared to cigarette 
smoking, but increased risk for accelerated loss of lung function.(38)Agricultural 
and dusty occupations are augments the risk of developing chronic bronchitis by 
two- to threefold and with smoking combination the risk increases to sixfold.(32,33) 
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Several specific occupational exposures including coal mining, gold mining,cotton 
textile dust, welding, construction, plastic manufacturing and utility all have been 
suggested as risk factors for chronic airflow obstruction. The high prevalence of 
smoking among workers in certain occupation has been a major confounding 
factor. Occupational exposures to organic and inorganic gases and fumes also lead 
to higher vulnerability to COPD. Workers exposed to cadmium can develop 
emphysema. [39] 
OUTDOOR AIR POLLUTION: 
This public health problem occurs mainly from the emission ofpollutants 
from motor vehiclesandindustries.(29)Particulate pollutants, ozone, nitrogen dioxide 
and sulphur-dioxide areproduce airway oxidative stress, bronchial hyper reactivity, 
systemic as well as pulmonary inflammation, reduction in airway mucosal cilliary 
activity and amplification of viral infections.(30) In community-based study,higher 
traffic density wasassociated withdiminished FEV1 and  
FVC.(31)In low-income countries outdoor air pollutant levels tend to be higher.  
INDOOR AIR POLLUTION:   
Commonly theindoor air pollutants are environmental tobacco 
smoke,particulatematter, carbon monoxide (CO), NO2, volatile organic compounds 
andbiological allergens.The major indoor air pollutants that are related to the 
development of COPD are tobacco smoke and biomass exposure.(34)The 
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contributing factors for indoor air pollution are wood, animal dung,crop residues 
and coal are burned in open fires and poorly functioning stoves in poorly ventilated 
indoors are the contributing factors for indoor air pollution. Women’s are spending 
more time in indoors for cooking than men, andexposed to biomass fuel 
combustion products, so theyare prone to develop COPD.(36,37) In India exposure to 
biomass smoke is a major one and burning of mosquito coils at homes are common 
indoor pollutants for the genesis of COPD. Burning one mosquito coil is equivalent 
to around 100 cigarettes because it emits as much particulate matter pollution.(35) 
LOWER RESPIRATORY TRACT INFECTIONS: 
Previous tuberculosis, childhood asthma and respiratory infections are the 
risk factors to develop COPD.Childhoodlower respiratory tract infections might 
produce permanent damage or impair growth and development of the lung. In 
Lung Health Study COPD exacerbations in smokers were associated with an 
additional loss of FEV1 of 7 ml per year for those having one exacerbation per 
year. 
LOW SOCIOECONOMIC STATUS: 
COPD incidence, prevalence, morbidity and mortality rates are inversely 
relatedtosocioeconomic status. Poor housing condition, overcrowding, poor 
environment, poor nutrition, alcohol, tuberculosis and recurrent lower respiratory 
infections are the common risk factors in low socioeconomic status people.  
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HOST FACTORS: 
GENETIC FACTORS: 
 The association between the development of early-onsetemphysema and 
alpha1- antitrypsin deficiency was first described by Eriksson in 1963. (40)In 
alpha1-AT deficiency premature development of pan lobular emphysema and early 
decline in lung function occurs. M allele is fornormal alpha1 antitrypsin.Mutation 
in the SERPINA1 gene [located on the long arm of chromosome 14 (14q31-32.3)] 
and forms  the Z allele results severe alpha1-antitrypsin deficiency(41).In COPD  
variety of genes including beta1microsomal epoxide hydroxylase-1,tumor necrosis 
factor alpha and transforming growth factor are associated for pathogenesis. 
ATOPY AND AIRWAY HYPERRESPONSIVENESS: 
Dutch workers in the 1960s proposed that smokers with COPD and 
asthmatics shared common characters like airway hyper responsiveness, allergy 
and eosinophilia.(42) Atopic individuals have high serum IgE and eosinophil levels. 
The probable mechanisms for increased AHR in smokers with COPD: 
1. Shortening of the airway smooth muscle and increased thickening of the 
airway wall. 
2.  Inhaled aerosolsdeposition is in the centrally that result of airways 
obstruction, 
3.In emphysema alveolar wall loss results in loss of airway wall support. 
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4.Airway wall edema is due toincreased permeability of airway epithelium. 
ASTHMA:  
Childhood asthma,chronic untreated and partially treated asthma can 
progress to fixed airflow obstruction. Tucson epidemiological studies had showed 
that asthmatics have a twelvefold increase risk of develops COPD than non-
asthmatics. 
PATHOGENESIS: 
The probable pathogenesis of COPD is proteinase-antiproteinase hypothesis, 
immunological, imbalance of oxidant-antioxidant,apoptosis,systemic 
inflammation, and ineffective repair.(44) 
PROTEINASE-ANTIPROTEINASE HYPOTHESIS 
In healthy lungs damage does not occur because the release of proteolytic 
enzymes from inflammatory cells inactivated by inhibitors. In condition of 
excessive enzyme load or where there is functional or absolute defic iency of 
antiproteinase, an imbalance develops between proteinases and antiproteinase. 
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 This leads to degradation ofconnective tissue in alveolar wall and 
development of emphysema. Cigarette smoke stimulate the airway epithelium and 
to trigger the airway remodeling. (46) In chronic smokers haveaccumulation of 
neutrophils, activated macrophages and CD8+ T lymphocytes in the distal airways 
and alveolar spaces.(45)The activated neutrophils produce moreneutrophil 
elastase.Matrix metalloproteinase (MMP) activity is increased in COPD.MMP-2, 9 
and 12 are increased in smoking associated emphysema. Other proteases that play 
a role in the COPD pathogenesis are cathapsins S, L, G and proteinase-3.(47)MMP 
andneutrophil elastase degrades the elastin fragments of the alveolar wall and leads 
to thedevelopment of emphysema.  
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IMMUNOLOGICAL MECHANISM: 
COPD patients have more numbers of neutrophils in sputum and lung tissue. In 
smoking-induced COPD immunoglobulin free light chains and IgE levels are 
increased.(48,49) 
OXIDANT AND ANTIOXIDANT BALANCE: 
Reactive oxygen species (ROS) in cigarette smoke or released by inflammatory 
cells and structural cells of the lungs in response to smoke may lead to lung 
injury.In smokers there isincreased theROS (hydrogen peroxide, hydroxyl radicals, 
superoxide radicals, H2O2, and 8-isoprostane)and decreased plasma 
antioxidantsproducts such as 4-hydroxynonenal, 3-nitrotyrosine. Oxidative attack 
may inactivate antiproteases. Due to decreased production of inactivated histone 
deacetylases oxidative damage occurs and this leads to a prolonged inflammatory 
response.Vasodilation and endothelial cell growth impairs in Oxidative stress. 
Oxidants modify the elastin and the modified elastin is more susceptible to 
proteolysis. Oxidant augments matrix degrading capacity which can promote 
emphysema.(50) 
INFLAMMATION 
Smoking and inhaled irritants lead to recruitment of inflammatorycells in the lungs 
and airways.These recruited cellproducts injure the lung tissue and disrupt the 
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normalmechanisms of repair. In COPD neutrophils, eosinophil’s, macrophages, 
and lymphocytes are associated for inflammation. Interleukin-8 (IL-8), 
macrophage inflammatoryprotein-1α (MIP-1α), and monocyte chemo-attractant 
protein-1(MCP-1) are up-regulated in bronchiolar epithelium in COPD. CD4+ and 
CD8+ T cells and B cells accumulate in alveolar and airway tissue in COPD. 
Among these cells CD4+ are predominantly elevated. 
SYSTEMIC INFLAMMATION: 
Pro-inflammatory cytokines andchemokine’s are released into the circulation as a 
result of persistent pulmonary inflammation.(51) These mediators  stimulate bone 
marrow,liver and adipose tissue to release excessive amounts of leucocytes, IL-6, 
IL-8,C-reactive protein (CRP), fibrinogen and tumor necrosis factor-α (TNF-α) 
into the circulation.(52,53) Systemic inflammation may initiate or worsen the 
comorbid illness, such as normocytic anemia,IHD, Cardiac failure,osteoporosis,  
cancer lung, diabetes and depression. 
APOPTOSIS: 
InCOPD patients lung apoptotic alveolar endothelial and epithelial are 
increases.Mediators involved in apoptosis are,vascular endothelial growth factor, 
caspase-3 and ceramide.  
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INEFFECTIVE REPAIR: 
The repair in emphysema not effective is due to the damaged alveoli have limited 
ability is to repair. 
PATHOPHYSIOLOGY 
 In COPD Pathophysiological changes occurs in central airways, peripheral 
airways, paranchyma of the lung and pulmonary vasculature. The defining 
physiological feature ismaximal forced expiratory flow reduction is persistent. The 
typical features areincreased theairway resistance, increased theresidual volume, 
increased the res idual volume/total lung capacity ratio,decreased the inspiratory 
capacity, maldistribution of ventilation, and mismatching of ventilation-
perfusion.Loss of lung elasticity, increasedairways resistanceand decreased 
lungcompliance are the factors that reduce forced expiratory flow. 
Pathophysiological changes occur in the following order in COPD. 
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MUCUS HYPER SECRETION: 
In COPD patients with predominant central airway involvement the common 
featutre is mucus hypersecretion.It is due to enlargement submucus glands and 
metaplasia with increased numbers of globet cell in chronic irritation of the 
respiratory epithelium.   
AIR FLOW LIMITATION: 
The characteristic feature of COPD patient is decrease in FEV1 and FEV1/FVCratio 
probably due to inflammation, fibrosis and luminal exudates 
in small airways.(54) 
HYPERINFLATION: 
It is described by decreased inspiratory capacity and increase in functional 
residual capacity. Hyperinflationproduces the following effects. 
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(1) Decreases the zone of apposition between the diaphragm and the abdominal 
wall, rib cage movement are hindering. 
(2) Diaphragmatic muscle fiber length shortens, decreasing the force that can be 
generated by the diaphragm. 
(3) The radius of curvature of the diaphragm increases and decreasing 
transpulmonary pressure (at constant tension). 
(4) Diaphragmatic muscle fibers medially directs and impairing inflation with 
diaphragmatic contraction. 
PULMONARY GAS EXCHANGE ABNORMALITIES 
In COPD Ventilation–perfusion (V ·a/Q ·) mismatching is the most vital 
cause of decreased pulmonary gas exchange. Other less importantcauses are 
alveolar hypoventilation, impaired alveolar–capillary oxygen diffusion and 
increased shunt. In COPD patient’sventilation distribution is unequal. As a result 
of emphysema reduction in blood flow due to local destruction of alveolar vessels, 
hypoxic vasoconstriction in alveolar hypoxemic areas and passive vascular 
obstruction as a result of increased alveolar distension and pressure.This results in 
hypoxemia and hypercapnea. 
PULMONARY HYPERTENSION: 
In patients with long term COPD the development of pulmonary 
hypertension is due to hypoxic vasoconstriction of pulmonary 
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arteries.Progressivepulmonary hypertension leads to the development ofventricular 
hypertrophy and corpulmonale. 
SYSTEMIC FEATURES: 
 
 COPD with smoking history have the higher comorbidities was observed in 
the ECLIPSE study.(62) The following comorbidities associated with COPD are 
cardiovascular disorders (Hypertension, CAD and Chronic cardiac failure), 
metabolic diseases (metabolic syndrome, obesity and diabetes), bone disease 
(osteopenia and osteoporosis), skeletal muscle weakness, anemia, stroke, lung 
cancer, cachexia, depression and cognitive decline.(63) 
 Cachexia is a common feature of severe COPD.The probablemechanism of 
cachexia is low testosterone levels, increased catecholamine synthesis and 
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increased levels of pro-inflammatory cytokines. (55,56,57) The fat-free mass is 
significantly reduced in COPD.(58)There may be weakness and loss of skeletal 
muscle mass due toincreased apoptosis and disuse of the muscle. Usually the 
skeletal muscle mass loss is seen in thighs and upper arms.(59)The dysfunction of 
theskeletal muscle is exaggerated by poor nutrition, hormonal changes and use of 
corticosteroids.(61)The skeletal muscle dysfunction results in reduced exercise 
intolerance and with symptoms of fatigue and dyspnea.(60)In patients with severe 
COPD the factors contribute to the generalized muscle weakness are hypercapnia, 
hypoxemia, infection, electrolyte and mineral defic iencies.In spite of a normal or 
increased dietary intake weight loss is more common in severe COPD. Systemic 
inflammation, increased oxidative stress, increased thrombotic tendency and 
neuro-humoral disturbances are the risk factors leading to the development of 
cardiovascular disease in COPD patients. (64) The osteoporosis risk increases by 
1.9-fold in COPD patients and by 2.4-fold in severe COPD patients.(65) The 
probable etiology for the bone loss are smoking, sedentary lifestyle, low body mass 
index, vitamin D deficiency, hypogonadism,  and use of glucocorticoids.(66)COPD 
patients are more vulnerable to develop fractures particularly vertebral fractures. In 
COPD patient’s risk of lung cancer is high in smokers than nonsmokers.In 
COPDpatient’sprevalence of depression is higher in females, current smokers, and 
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severe disease.(67, 68)Anemia is common than polycythemia and it reduce the 
functional capacity. 
CARDIO VASCULAR CHANGES: 
 Pulmonary hypertension and corpulmonaleare the consequence of chronic 
alveolar hypoxia; the secondary contributions are from destructionof the alveolar 
capillary bed, lung hyperinflation and increased blood viscosity.The chronic 
alveolar hypoxia produces a characteristic remodeling of the pulmonary arteries.  
The three major components remodeling are. 1. Extension of the medial muscle 
into the pulmonary arterioles.[69,70]2.Proliferation of muscle that becomes 
progressively thickens and occludes the vascular lumen. Insevere cases Intimal 
fibrosis may occur. 3. Inner muscular tube develops in the smallpulmonary 
arteries.(71)In the late course of COPD hypoxemia and hypercapnia leads to 
pulmonary arterial hypertension. 
The followingpulmonary vasculature changes occur in the pulmonary vascular bed 
in COPD patients. 
1. Intimal thickening of the small pulmonary arteries is the earliest change.It is 
due to worsening of the airflow limitation.(72,73) 
2.  Medial hypertrophy of the muscular pulmonary arteries.(74) 
In patients with COPD pulmonary arterial thrombosis maybe due to 
Peripheral airwayinflammation.[75] 
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In COPD patients the following factors contribute to develop of pulmonary arterial 
hypertension: 
1. Pulmonary vascular bed destruction 
2. Blood gas tensions abnormality 
3. Pulmonary mechanics abnormality 
4.Increased Cardiac output 
5. Alteration in blood volume  
6. Blood velocity Increased 
7. Abnormal endothelium 
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Classically, pulmonary hypertension in emphysema has been attributed to the  
following factors: 
1.Hypoxia leading to vasoconstriction and vascular remodeling 
2. Hyperinflation compressesthe alveolar vessels and pulmonary vasculatureby 
physical obliteration. 
3. Other possible influences include elevated end-expiratory intrathoracic pressure 
due to dynamic or static hyperinflation or use of expiratory muscles.(77)In smokers 
theproduct of tobacco produces inflammatory changes and pulmonary vascular 
remodeling.(82)The imbalance between vasoactive constrictor and dilator 
substances produce pulmonary hypertension.Nitric oxideinhibits cell 
proliferationinthe pulmonary vasculature and prevents vascularremodeling. In 
COPD patients with hypoxemia there is a reduction in nitric oxide levels and 
development of pulmonary hypertension. (76)Oswald-Mammoser and colleagues 
observation had shown that the worsening of pulmonary hypertension is directly 
associated with severity of airflow obstruction.(80,81) Burrows and coworkers found 
that emphysematous patients had higher pulmonary vascular resistance andlower 
cardiac output.(79) 
 Corpulmonale was defined by a WHO expert committee as “hypertrophy of 
the right ventricle resulting from diseases affecting the function and structure of 
the lungs, except when these pulmonary alterations are the result of diseases that 
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primarily affect the left side of the heart”. COPD patients have a highpulmonary 
vascular res istance as a result ofhypoxia.This causesincreased workload on the 
right ventric le leading toright ventricular hypertrophy(RVH), right ventricular 
dilatation and right heart failure.(77)In COPD patients the earliest sign of RV 
pressure overload is concentric right ventricular hypertrophy. The capacity of the 
RV to adapt to a high after load is overwhelmed duringacute 
exacerbations,overwhelmhence precipitating RV failure.(82) 
In RV dilation there will be an increase in end-diastolic volume that shifts 
the inter-ventricular septum into the left ventric le to reduce LVend-diastolic 
volume and diastolic compliance.(82)In COPD large intra-thoracic pressure changes 
and long standing  RV pressure overload can produce RV hypertrophy and 
dilatation that shift the  inter-ventricular septum into LV cavity during systole and 
results in the limitation of left ventricular cavity dimensions, contractility, 
compliance, and  rise of the left ventricular diastolic pressure(88,89,90,91)and alteration 
of LV systolic function.
(84,85,86,87)
 
 In pulmonary hypertension blood flow through bronchial circulation 
increasesand produces right-to-left shunt, resulting in s ignificant amount of 
desaturation of left atrial blood that contributes to the progressive hypoxia. The 
myocardial contractility is decreased due todecreasedarterial oxygen 
tension.(94,95,97) 
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 In Hypoxia the accumulation of excess toxic metabolic products like K
+
, H
+
 
and lactic acidin the cardiac tissue  impair the myocardial contractility  producing 
diminished LVEF(88). 
Endothelial surface enzymes control the level of circulating compound such as 
bradykinin, serotonin, angiotensin and adenine nucleotides. During hypoxia there 
is endothelial dysfunction and altered enzyme activity may lead to atherosclerosis 
and ischemia of cardiac muscles.
(96)
 
Hyperinflation, increased work of breathing, and raised intra-thoracic pressures 
also have an impact on the LV functioning.  
 Sabit et al. had shown that the subclinical COPD have right ventricular 
dysfunction may be related to airways obstruction and left ventricular 
dysfunctionrelated to stiffness of the arteries. RV dysfunction is due to raised 
pulmonary arterial pressure and LV dysfunction is associated with increases 
afterload due to increased aortic stiffness.(93) 
Mechanisms of impaired LV filling in very severe COPD include alveolar hypoxia 
and pulmonary vascular changes, hyperinflation of the pulmonary system, and 
ventricular interdependence.In very severeCOPD hyperinflation can cause increase 
intra-thoracic pressure that exceedpulmonary venous pressure and leads to 
reductions in blood volumes of both ventric les. 
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The following are also the mechanisms of heart failure. 
        1. Renin-angiotensin aldosterone system activation. 
        2. Sympathetic nervous system activation andvasopressin. 
        3. Generation of pro-inflammatorycytokines. 
The above mentioned mechanisms are responsible for 
increasingvascularresistance, increasing heart rate, worsening myocardial 
perfusion, alteringrenal blood flowandatrialfibrillations.Ischemia and arrhythmias 
are worsening the LVdysfunction and precipitating cardiac failure.(83) Skeletal 
muscle alterations increase the LV strain and dysfunction under the conditions of 
stress. Acute infections, severe anemia,hypertensive emergencies, cardiac 
arrhythmias (MAT, AF), ischemia, pulmonary embolism and cardio toxicdrugs 
may precipitate HF in COPD patients. 
SUPRAVENTRICULAR ARRHYTHMIAS: 
 Supraventricular tachyarrhythmiasare common in patients with COPD, as a 
consequence of right atrial enlargement,increased adrenergic tone, hypoxemia and 
treatment with theophylline,anticholinergics and bronchodilators. 
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EDEMA: 
 
COPD patient’salterations in salt and water balance are due to hypoxia and 
hypercapnia. The activation of renin–angiotensin system bydiminution of renal 
blood flow andraise in AVP as a result of alteration in the blood gases 
concentration. 
Hypercapnia increases the catecholamine release via a neural mediated action and 
reduces the renal blood flow. In pulmonary hypertension increase the release of 
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ANP is due to increases theatrial stretch.[98]ANPhas important beneficial effectsthat 
could act to prevent the formation of edema in patients with COPD, including the 
promotion ofnatriuresis,[99]decreasesplasma renin activity, decreases angiotensin п 
andaldosterone production. [100]Therenin–angiotensin system activation 
overwhelms the protective mechanisms and leading to develops edema. 
PATHOLOGY: 
 In COPD patients the pathological changes occurs in the large and small 
airways and alveoli. 
 
 
Large airways:(Central airway-bronchi>2mm internal diameter): 
In chronic bronchitis, goblet cells become hyperplastic and the mucus glands 
are 
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enlarged.In smokers goblet cells increase innumber and extend to more 
peripherally.Bronchi also undergo squamous metaplasia.(52) 
 
 
Reid index quantifies thehypertrophy of the mucous gland.“Reid index is the ratio 
of the distance between the basement membrane of the airway epithelium and the 
cartilage to the thickness of the gland layer”, Normal ratio is 3:1. In normal 
individuals, it is 0.44+0.09.In chronic bronchitis, it is 0.52+0.08.If the sub mucosal 
layer thickness is >50% of bronchial wall thickness it is highly suggestive of 
chronic bronchitis. 
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Small airways(peripheral airways-bronchiole <2mm internal diameter): 
 Narrowing and destruction of terminal bronchioles are characteristic changes 
in COPD.  Airway inflammation andscarring of thesmaller airways are associated 
with airways obstruction. 
In COPD the following cellular events that occur in the small airways: 
1. Mucus secreting cells replaced by Clara cells  
2. Mononuclear cellinfiltration  
3. Goblet cell metaplasia.(50) 
 Theimportant finding is Smooth muscle hypertrophy .Thecauses of airway 
narrowingare excessive secretion of mucus, formation of edema, cellular 
infiltration and fibrosis.(52) 
Lung parenchyma(respiratory bronchioles andalveoli): 
Emphysema were first described by Laennec(101) and defined as“dilatation 
and destruction of lung tissue beyond the terminal bronchiole”.(102,103)Emphysema 
is described bydestruction of gas-exchanging air spaces.According to the 
distribution of enlarged airspaces within the acinar unit emphysema types 
described.  
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Centriacinar (syn. Centrilobular) emphysema:  
 This kind of emphysemais associated with tobacco smoking. The enlarged 
airspaces are c lustered around the terminal bronchiole. It ismore common in upper 
and lower lobes of the upper zones. 
Panacinar (syn. pan lobular) emphysema:  
 The enlarged airspaces are dispersed throughout the acinar unit .It is 
associated with α1-AT deficiency and found anywherein the lungs but more 
marked at the bases. 
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Periacinar (syn.Paraseptal or distalacinar) emphysema: 
The enlarged airspaces are along the edges of the acinar unit, where it is 
abuttingthe pleuraor vessel. 
Scar or irregular emphysema: 
 It is described as enlarged airspaces around the scar margins that are 
notrelated to the structure of the acinus. 
CLINICAL FEATURES: 
Symptoms: 
Cough with or without expectoration. 
Breathlessness 
Chest pain- may be related to intercostal muscle ischemia. 
Haemoptysis 
Weight loss, Effort intolerance,Ankle edema. 
Signs: 
- Nicotine staining of fingers and teeth. 
- Nonspecific features of over inflation of the lungs with horizontal ribs, splaying 
of lower costal margin &widened xiphisternal angle. 
-Paradoxical inward movement of lower ribs (Hoover’s sign). 
- Cardiac dullness reduced. 
- Intensity of breath sounds reduced. 
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- Crepitation’s, Expiratory wheezes. 
-Pursed lip breathing. 
-RVH heave palpable in the subcostal angle or at lower sternal edge, loud P2. 
- Third sound audible in the left fourth intercostal space, Pan-systolic murmur at 
the left sternal edge, Right ventricular gallop rhythm, elevated jugular venous 
pressure, pedal edema and tender hepatomegaly in corpulmonale. 
 Predominant 
bronchitis 
Predominant 
Emphysema 
General 
Appearance 
Mesomorphic; 
overweight, 
dusky with suffused 
conjunctivae, warm 
extremities 
Thin, often emaciated, 
pursed lip breathing, 
anxious, normal or cool 
extremities 
Age, years 40 to 55 years 50 to 75 years 
Onset Cough Dyspnea 
Cyanosis Marked Slight to none 
Cough More evident than 
dyspnea 
Less evident than 
dyspnea 
Sputum Copious Scanty 
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Blue bloaters: 
 Development ofhypoxemia, hypercapnia polycythemia and edema occurs 
relatively early in blue bloaters.. 
Pink puffer: 
 Pink puffers are thin,dyspneicandpreserve blood gas values until late in the 
course of the disease and develop pulmonary hypertension inadvanced disease 
state. 
 
 
 
Upper respiratory 
Infections 
Common Occasional 
Breath sounds Moderately diminished Markedly diminished 
Corpulmonale Common Only bouts of RTI and 
also terminally 
Radiography Normal diaphragmatic 
position; cardiomegaly; 
lungs normal or having 
increased 
bronchovascular 
markings 
Small tubular heart; low 
flat 
diaphragm; Area of 
increased 
radiolucency 
Other names Blue bloater Pink puffer 
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INVESTIGATIONS: 
SPIROMETRY: 
 Spirometry is asound test of airflow limitation in patients with COPD. It is 
the goldstandard test for diagnosis and monitoring its progression. Normal curve 
has a brisk flow near total lung capacity, then a steady decline down to residual 
volume. Inspiratory limb is a smooth semicircle. With the development of disease 
in small airways the expiratory limb begins to dip at lower volumes. Spirometry 
measures the forced vital capacity (FVC),forced expiratory volume in one 
second(FEV1) and ratio of the two measurements(FEV1 /FVC).A low FEV1 and 
FEV1/ FVC ratio below the normal range is the diagnostic criteria for COPD.(104-
106)A post bronchodilator FEV1 / FVC ratio < 0.7 establishes the diagnosis of 
COPD. Asthma and COPD commonly coexist butCompared to the baseline FEV1 
value, asthmatic patients will have 12% or greater improvement after 15 minutes 
use of short-acting beta2 agonist inhalation and the FEV1 also increases by> 200 
ml. 
CHEST X-RAY:   
  Emphysematous changes-Hypertransluency, Transluency extends anteriorly 
up tothe 7th rib and posteriorly up to 9th rib. The other features are a Widened 
intercostal space along with low flat diaphram, tubular heart, increased pulmonary 
vascular markings and pulmonary artery dilatation.  
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FULL BLOOD COUNT AND HAEMATOCRIT:  
To identify anemia, polycythemia andleukocytosis 
SPUTUM CULTURE: 
 For identification of theorganism. 
BODY MASS INDEX (BMI): 
 For theassessment of prognosis. 
ALPHA-1 ANTITRYPSIN: 
 Alpha-1 antitrypsin deficiency is an uncommon, but not rare a condition 
associated with premature emphysema. Testing for α1-antitrypsin deficiency is 
indicated in the likely hood of having the disorder. 
 
A serum alpha-1 antitrypsin concentration level below 15-20% of the normal value 
is highly suggestive of homozygous alpha-1 antitrypsin deficiency. 
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Transfer factor for carbon monoxide (TLCO) and transfer coeffic ient (KCO): 
 To investigate symptoms thatseems disproportionate to the Spiro metric 
impairment. The transfer factor test for carbon monoxide measures the ability to 
move carbon monoxide from inhaled gas to hemoglobin in the alveolar capillaries. 
A reduction in transfer factor (TLCO) and transfer coeffic ient (KCO) is the best 
functional indicator of the presence and severity of pulmonary emphysema.(107) 
 In this context KCO is more specific than TLCO.(108) Asthma may reduce TLCO 
when severe but KCOtends to be high in asthma. Emphysema with its destruction 
of alveolar capillary membrane results in large air space, decreased area for gas 
transfer & reduction of TLCO & KCO. 
PULSE OXIMETRY:  
 Assessthe Spo2level and need for oxygen therapy. 
 If corpulmonale present, or if FEV1 < 50% predicted it is indicated. 
ARTERIAL BLOOD GAS MEASUREMENT: 
 In acute exacerbations of COPD,to confirm the degree of hypoxemia and 
hypercapnia the arterial blood gases measurement is important.It is 
recommendedin FEV1 <40%, signs of respiratory failure or right heart failure. In 
acute exacerbationblood gas analysis evaluates the severity, prognosis, the need for 
oxygen therapy with reference to invasive or noninvasive ventilator support. 
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CT SCAN OF THE THORAX: 
 CT chest is recommended only if there is a doubt inthe diagnosis of COPD. 
ECG: 
 The characteristic ECG pattern in patients with chronic obstructive 
pulmonary disease is due to the insulating effect of the hyperinflated lungs,altered 
position of the of the heart, and caudal displacement of the diaphragm. 
ECG changes in COPD 
 1. P waves >0.25 mV in lead II, III, or aVF – P pulmonale. 
2. P wave axis to the right of 80 degrees in the frontal plane. 
3. Lead I sign with an isoelectric P wave, QRS amplitude <0.15 mV, and  
 T wave amplitude<0.05 mV 
4. QRS amplitude in all limb leads <0.5 mV 
5. QRS axis to the right of 90 degrees in the frontal plane 
6. QRS amplitude <0.5 mV in lead V5 or V6; or R wave <0.7 mV in lead V5 or 
    R wave <0.5 mV in lead V6 
7. R/s >1 in V1 or R wave amplitude in V1 >5 mm, R/S ratio <1 in lead V5 or V6 
8. S1S2S3 pattern with R/S ratio <1 in leads I, II, and III- S1S2S3 syndrome. 
 9. Complete/ incomplete right bundle branch block 
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10.T wave - decrease in amplitude in all leads, may be inverted in right precordial 
leads 
 11. Right ventric le hypertrophy: 
                  -  Prominent terminal S waves in the left precordial leads. 
 - Right axis deviation. 
ECHOCARDIOGRAPHY: 
 Echocardiography is sensitive test to detect pulmonary hypertension, 
corpulmonale and left ventricular dysfunction in COPD patients. It is aneasily 
available, non-invasive technique that assesses the right ventricular hypertrophy, 
dilatation,pulmonaryartery pressure and ejection flow dynamics. In COPD 
patients,the hyperinflated lungs alter the sound wave transmission.(109) Two-
dimensional echocardiography gives important information on dynamics of cardiac 
structures and morphology (110).Continuous wave Doppler echocardiography may 
provide an estimate of pulmonary artery systolic pressure in the presence of 
tricuspid regurgitation. 
Echocardiography findings in COPD: 
Increase the pulmonary artery pressure. 
Tricuspid regurgitation. 
 Right ventricular wall thickening. 
        Increaseright ventricular volume. 
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 Reverse movement of the inter-ventricular septum. 
 Right atrium and ventric le enlargement 
Left ventricular cavity may be normal or reduced 
Right ventricular dysfunction. 
Systolic bowing of the inter-ventricular septum towards the left ventricle is a 
characteristic abnormality of right ventricular pressure overload and it is detected 
by two-dimensional echocardiography.[111]In patients who are difficult to image 
with 2-D echocardiography, MRI is usefulfor assessing RV structure. Pulmonary 
hypertensiondiagnosis is confirmed by Right-heart catheterization 
BNP AND N-TERMINAL BNP: 
 In corpulmonale BNP and N-terminal BNP levels are elevated,secondary to 
RV stretch. The severity of pulmonary hypertension and right ventricular 
distension may be estimated by BNP levels and also reflects the treatment efficacy. 
MANAGEMENT: 
  The overall approach to managing stable COPD should be characterized by 
an increase in treatment,depending on the severity of the disease and the clinical 
status of the patients.  
The therapeutic goals are: 
1. Preventprogression ofdisease (cessation of smoking)  
         2. Relive thedyspnea and respiratory symptoms  
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3.Improve daily activity and exercise tolerance  
         4. Decrease the frequency and severity of exacerbations  
         5. Treat the COPD exacerbations and complications. 
         6.Improve the health status  
         7. Mortality reduction 
Management strategies arepharmacotherapy and non-pharmacotherapeutic 
approaches that improve quality of life, activity levels and symptoms of COPD. 
PHARMACOTHERAPY: 
 Pharmacological treatment of COPD has to improve the symptoms, 
reduceexacerbations, hospitalizations, and improve the quality of life.Inhaled 
bronchodilators, corticosteroids, oral theophylline and oral phosphodiesterase-4 
inhibitor are useful in COPD. 
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 Bronchodilators are the mainstay in COPD pharmacotherapy. 
Bronchodilators reduce air trapping, breathlessness and improve quality of life. 
Bronchodilators can increase FEV1<10%.(52)Patients with mild COPD should be 
started onshort-acting inhaled beta2 agonist or ipratropium. If symptoms persist 
ipratropium( tiotropium) or  long-acting beta2 agonist (LABA)) is an alternative. 
Concurrent use of tiotropium and ipratropium is not routinely recommended. 
In moderate to severe COPD, the treatment iscombination of tiotropium and 
LABA.In recurrent exacerbations add inhaled steroids.(112)In acute exacerbations of 
COPD inhaled and systemic steroids have more beneficial.(113,114). Inhaled steroids 
have been shown to improve the lung function, symptoms,quality of life and to 
reduce the frequency of COPD exacerbations.(115,116,117) Long-term inhaled 
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corticosteroids use associated with an increased risk of pneumonia.(52) Oral 
corticosteroids have numerous side effects so it is not recommended as a long-term 
monotherapy.(52) 
 Theophylline is useful in persistent symptoms despite optimal inhaled 
therapy. Roflumilast is a phosphodiesterase-4 (PDE-4)inhibitor, it inhibit the 
intracellular cyclic AMP breakdown and reduces the inflammation. It is 
administered 500 mg OD orally and it reduces acute exacerbations.(118)Roflumilast 
used concurrently with LABA has been shown to reduce the acute 
exacerbations.(119,120) 
OXYGEN THERAPY: 
 The main goal of oxygen therapy is to maintain SpO2 ≥ 90% or PaO2 ≥ 60 
mmHg atrest. Supplemental O2 is routinely used for patients with exertional or 
nocturnal hypoxemia.Long-term oxygen therapy (LTOT) (>15 h per day) is useful 
in respiratory failure and with severe resting hypoxemia and has been found to 
have increased survival.(52) 
IMMUNIZATION OF THE PNEUMOCOCCAL AND INFLUENZA 
INFECTIONS:  
Pneumococcal vaccination for every 5-10 years 
 Influenza vaccination for yearly 
 
NON-PHARMACOLOGIC TREATMENT: 
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SMOKING CESSATION 
 In long-term smokerscessation ofsmoking is more effective to prevent the 
progress of the disease and has been found to reduce the decline of FEV1. 
PULMONARY REHABILITATION: 
 The components of pulmonary rehabilitation programme includesmoking 
cessation,nutrition counselling, exercise training and education. 
SURGICAL TREATMENT: 
 Lung volume reduction surgery is indicated in upper lobe emphysema. 
 
Lung transplantation: 
Lung transplantation is indicated in COPD patients who have FEV1 < 25% 
predicted or the paCO2 is > or = 55 mm Hg. 
In respiratory failure either non-invasive mechanical ventilation or mechanical 
ventilation indicated. 
CORPULMONALE: 
 The primary treatment of corpulmonale consists of continuous oxygen to 
overcome hypoxemia and diuretics to control peripheral edema. Digitalis is useful 
for rate control of atrial fibrillation. 
PROGNOSIS: 
 Factors that predict poor survival in COPD are low FEV1, active smoking 
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status, hypoxemia, poor nutrition, the presence of corpulmonale, resting 
tachycardia, low exercise capacity, severe dyspnea, poor health-related quality of 
life, anemia, frequent exacerbations, co-morbid illnesses, and low carbon 
monoxide diffusing capacity. COPD prognosis is based onthe BODE index. 
 
 BODE score greater than 7 is associated with a 30 percent 2-year mortality. 
                          Score of 5 to 6 is associated with 15 percent 2-year mortality.  
 Score is less than 5, the 2-year mortality is less than 10 percent. 
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AIM OF THE STUDY: 
To study the prevalence of LV systolic dysfunction in COPD patients and to 
assess the possible risk factors contributing to the development of LV 
systolic dysfunction.  
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METHODS AND MATERIALS: 
Study group : COPD patients admitted in the department of  
  General Medicine  
Study design : Observational study  
 Place of Study  :  Govt. Royapettah Hospital 
Sample size  : 50 patients 
Duration of study : 6 months (May 2013-October 2013) 
Conflict of interest:  Nil 
 Hazards to study population: Nil 
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Clearance was obtained from the ethical committee of Government Kilpauk 
Medical College. 
METHODOLOGY: 
In patients with COPD, CBC with ESR, RBS, FBS, PPBS, Blood urea & 
creatinine, lipid profile, LFT, Urine Routine, Ultra sonogram Abdomen, Chest X-
ray, Pulse Oximetry for SPO2, Pulmonary function test, ECG, ECHO will be done 
after obtaining written informed consent. Severity COPD is assessed by Gold 
criteria. LVEF was measured by 2D Echo. PFT was assessed by Spirometry. LVEF 
was compared with severity of COPD and possible risk factor behind such 
development. 
Inclusion criteria : 
 AllCOPD patients. 
Exclusion criteria : 
1. Systemic Hypertension  
2. Diabetes Mellitus 
3. H/o congenital, acquired valvular heart disease 
4. IHD 
5. Cardiac arrythmias  
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6. Chronic AF 
7. Complete RBBB or LBBB 
8. H/o heart failure  
9. Chronic kidney disease 
10. Patients with poor echo window 
11. Patients unable to perform PFT 
Data collection: 
The data of each patient will be collected in a specifically prepared proforma 
and includes demographic details proper history, clinical features, CBC with ESR, 
RFT, FBS, PPBS, LFT, Total Cholesterol& Triglycerides, Ultrasound Abdomen, 
chest X-ray, ECG, PFT and ECHO 
A diagnosis of COPD should be considered in: 
Persistent cough with expectoration for 3 months in two consecutive years 
Chronic cough - Present intermittently or present throughout the day 
Chronic sputum production 
 Dyspnea that is- Progressive (worsens over time) 
                          - Persistent (present everyday) 
                          - Worse on exercise 
                         - Worsens during respiratory infections 
Leg swelling for corpulmonale 
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History of exposure to risk factors –smoking, air pollution 
On examination: pallor, edema, elevated JVP,purse lip breathing,pulse,CVS-
P2loud,RS-wheeze,crepitations. 
Chest X-ray: evidence of Hypertransluency, low flat diaphragm,widened 
intercostal space, and tubular heart. 
SPIROMETERY:  
 COPD is diagnosed only if FEV1 <80%predicted and FEV1/FVC <0.7 
(mild COPD FEV1 >80% predicted) 
 
 Performance of Spirometery: 
 Spirometry was done according to the guidelines published by the 
British Thoracic Society. Patient’s sex, age and height are entered in the 
spirometer.Patientswereseated comfortablyandmaneuver demonstrated. They were 
asked to take deep full inspiration. Good seal was maintained with the mouth piece 
of spirometry.Patients were asked to blow the breath out, forcibly as hard and as 
fast as possible, until there is nothing left to expelfor at least 6 seconds and to a 
maximum of 15seconds.The results (FEV1 & FEV 1 /FVC) appear on the display 
andare noted. The results of the measurement were accepted only smooth & cough 
free. This maneuver was repeated three times.  Best of the three consistent readings 
of FEV1 and FVC were taken.Reversibility test was done thirty minutes after200 
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mcgof salbutamolnebulization to rule out bronchial asthma (reversibility more than 
12% FEV1&FEV1 increases> 200 ml). 
Calculation of % improvement 
 FEV1 (post bronchodilator) – FEV1 (base line)  
                     -------------------------------------------------------------- X 100 
 FEV1 (base line) 
FEV1 / FVC % < 70 is used to diagnose COPD 
For assessment of Severity of COPD by FEV1% 
 
The COPD severity was assessed by GOLD criteria. 
 
Electrocardiograph was taken and looked for evidence of pulmonary hypertension 
in chronic obstructive airways disease. 
All patients were subjected to both 2 D and Doppler Echocardiogram 
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THE FOLLOWING PARAMETERS ARE OBTAINED FROM 
ECHOCARDIOGRAM. 
EJECTION FRACTION: 
 M-mode or two-dimensional echocardiographic measurement of LV 
dimensionfrom the mid-ventricular level is used to calculate LVEF as follows: 
LVEF = (LVEDD2 – LVESD2) / LVEDD2  
EF-50% - 75%is normal.EF <50% istaken as LV systolic dysfunction. 
DIASTOLIC FUNCTION OF THE LV: 
 The trans mitral pressure gradient or the relationship between LA and LV 
Pressures are accurately reflected by mitral inflow Doppler velocities. Diastolic 
filling is usually c lassified initially on the basis of the peak mitral flow velocity of 
the early rapid filling wave (E), peak velocity of the late filling wave caused by 
atrial contraction (A), E/A ratio, and deceleration time (DT), which is the time 
interval for the peak E velocity to reach zero baseline. Diastolic dysfunction can be 
graded according to the diastolic filling pattern. 
Grade 1 -mild dysfunction-(E/A ratio <1.0 and DT >240 milliseconds). 
Grade 2 -moderate dysfunction- (E/A ratio of 1 to 1.5 and normal DT 160 to 240 
milliseconds). 
Grade 3 (severe reversible dysfunction)&Grade 4 (severe irrevers ible dysfunction) 
–(E/A ratio higher than 2, and shortened DT < 160 milliseconds) 
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PULMONARY ARTERY PRESSURES: 
Flow velocities recorded with Doppler echocardiography are used to 
determine various intra-cardiac pressures. Pulmonary artery systolic pressure equal 
to the calculated RV systolic pressure.  RV systolic pressure can be obtained by 
adding the estimated RA pressure to the TR velocity.TR velocity reflects the 
systolic pressure difference between the right ventricle and rightatrium .Tricuspid 
regurgitation velocity was recording by continuous-wave Doppler 
echocardiography.  
 
 
PA pressure levelsin PHT. 
                 PHT GRADE                 PA  PRESSURE 
           MILD        30 – 50 mmHg 
           MODERATE        50 – 80 mmHg 
           SEVERE >80 mmHg 
PULMONARY VELOCITY ACCELERATION TIME(PVAT):  
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 There may be situations in which no tricuspid regurgitation is present or the 
signal is inadequate to obtain reliable measurements. PVAT also used toassess the 
severity of PHT. 
 
 
 
 
 
RA/RV dilation and main pulmonary artery diameter noted and correlated with the 
severity of PHT. 
OBSERVATION 
Table1: SEX DISTRIBUTION: 
 
Sex group Frequency Percentage 
Male 40 80.0 
Female 10 20.0 
              PHT SEVERITY                   PVAT 
              Normal >120 milliseconds 
              MILD 100 – 120 milliseconds 
             MODERATE 80 – 100 milliseconds 
             SEVERE <80 milliseconds 
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Total 50 100.0 
 
 
 
In our study the prevalence of COPD is more in males. Male: Female ratio is 4:1. 
 
 
Table 2: AGE DISTRIBUTION:                                                                                                                            
Fig 1: SEX DISTRIBUTION
Male
Female
Age (years) Frequency Percentage 
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Lower age limit 40 was selected because many of the studies reported thatthe 
 
41-50 11 22.0 
51-60 21 42.0 
61-70 13 26.0 
> 70 5 10.0 
Total 50 100.0 
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overall prevalence of COPD is higher in age group more than 40 years. In ourstudy 
prevalence of COPD is more in the age group 51 – 60 years. i.e., 42% of patients 
belong to 51- 60 years. 
Table 3:SMOKING INDEX AND COPD  
 
Smoking Index Frequency Percentage 
No smoker 15 30.0 
< 100 12 24.0 
101-300 19 38.0 
> 300 4 8.0 
Total 50 100.0 
  
Smoking index is taken as a parameter because in India number of cigarettes,   
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Fig 3: Smoking Index and COPD
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Beedis per pocket were quiet variable and weight of Beedis is widely different in 
different brands. More importantly Indian smokers often describe their smoking 
habit by the total number of cigarettes/Beedis per day rather than the number of 
pockets(121). 
               SMOKING INDEX                          GRADE 
<100  Mild smoker 
              101 – 300  Moderate smoker 
>300 Heavy smoker 
 
38% of our subjects were moderate smokers and 30% were nonsmokers 
. 
 
Majority of the smokers have moderate to severe COPD.  91.7% mild smokers and 
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 84.2% of the moderate smokers had moderate COPD. 75% heavy smokers have 
severe COPD.“p” value is significant. Severity of COPD is directlyrelated to the  
smoking index . 
Table 4:SMOKING INDEX AND SEVERITY OF COPD 
 
 
 
 
Smoking Index 
 
 
Severity of COPD Total 
 
p value 
Mild Moderate Severe 
Non smoker Number of persons 5 7 3 15 
 
 
 
 
 
0.001** 
 
 
% of nonsmokers  33.3% 46.7% 20.0% 100.0% 
% within Severity of COPD 83.3% 20.0% 33.3% 30.0% 
< 100 Number of persons 1 11 0 12 
 
 
% within Smoking Index 8.3% 91.7% .0% 100.0% 
% within Severity of COPD 16.7% 31.4% .0% 24.0% 
101-300 Number of persons 0 16 3 19 
 
 
% within Smoking Index .0% 84.2% 15.8% 100.0% 
% within Severity of COPD .0% 45.7% 33.3% 38.0% 
> 300 Number of persons 0 1 3 4 
 
 
% within Smoking Index .0% 25.0% 75.0% 100.0% 
% within Severity of COPD .0% 2.9% 33.3% 8.0% 
Total 
Number of persons 6 35 9 50 
 
% within Smoking Index 12.0% 70.0% 18.0% 100.0% 
% within Severity of COPD 100.0% 100.0% 100.0% 100.0% 
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Table 5: DURATION OF SMOKING AND SEVERITY OF COPD 
 
Duration of 
Smoking in 
years 
 
 
Severity of COPD Total 
 
p 
value Mild Moderate Severe 
Non smoker Number of Persons 5 7 3 15 
 
 
 
 
 
 
 
 
 
 
.026* 
 
 
% among nonsmokers 33.3% 46.7% 20.0% 100.0% 
% within Severity of 
COPD 83.3% 20.0% 33.3% 30.0% 
< 10 Number of Persons 1 4 0 5 
 
 
% within Duration of 
Smoking in years  20.0% 80.0% .0% 100.0% 
% within Severity of 
COPD 16.7% 11.4% .0% 10.0% 
11-20 Number of Persons 0 12 1 13 
 
 
% within Duration of 
Smoking in years  .0% 92.3% 7.7% 100.0% 
% within Severity of 
COPD .0% 34.3% 11.1% 26.0% 
21-30 Number of Persons 0 9 2 11 
 
 
% within Duration of 
Smoking in years  .0% 81.8% 18.2% 100.0% 
% within Severity of 
COPD .0% 25.7% 22.2% 22.0% 
> 30 Number of Persons 0 3 3 6 
 
 
% within Duration of 
Smoking in years  .0% 50.0% 50.0% 100.0% 
% within Severity of 
COPD .0% 8.6% 33.3% 12.0% 
Total 
Number of Persons 6 35 9 50 
 
% within Duration of 
Smoking in years  12.0% 70.0% 18.0% 100.0% 
% within Severity of 
COPD 100.0% 100.0% 100.0% 100.0% 
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In our study report those who smoked more than 10 years had moderate to severe 
obstruction and 50% of the smokerswho smoked more than 30 years had severe 
obstruction. ‘p’value is significant. prolonged duration of smoking  is associated 
with Increased severity of COPD. 
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Table 6:SOCIO ECONOMIC STATUS AND SEVERITY OF COPD 
 
 
 
Socio 
Economic 
Status 
 
 
Severity of COPD Total 
 
p value 
Mild Moderate Severe 
Low Number of Persons 3 26 9 38  
 
 
 
 
0.03* 
 
 
% within Socio 
Economic Status 7.9% 68.4% 23.7% 100.0% 
% within Severity 
of COPD 50.0% 74.3% 100.0% 76.0% 
Middle Number of Persons 3 9 0 12 
 
 
% within Socio 
Economic Status 25.0% 75.0% .0% 100.0% 
% within Severity 
of COPD 50.0% 25.7% .0% 24.0% 
Total Number of Persons 6 35 9 50  
% within Socio 
Economic Status 12.0% 70.0% 18.0% 100.0% 
% within Severity 
of COPD 100.0% 100.0% 100.0% 100.0% 
 
Economic status is inversely related to COPD. Our study shows 76% of the COPD 
patients belong to low socio economic status due to poor housing condition, 
overcrowding, poor environment, poor nutrition, alcohol, smoking and recurrent 
lower respiratory infections.  
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Table 7:SEVERITY OF COPD DISTRIBUTION 
 
 
 
Severity of COPD Frequency Percent 
Mild 6 12.0 
Moderate 35 70.0 
Severe 9 18.0 
Total 50 100.0 
 
 
Most of them are (70%) are moderate COPD. 
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Table 8: CORPULMONALE AND SEVERITY OF COPD 
 
Clinical 
Features of 
Corpulmonale 
 
 
Severity of COPD 
Total 
 
p value 
Mild Moderate Severe 
Present Number of 
Persons 0 0 6 6 
 
 
 
 
 
 
 
<0.001** 
 % within 
Clinical 
Features of 
Corpulmonale 
.0% .0% 100.0% 100.0% 
 % within 
Severity of 
COPD 
.0% .0% 66.7% 12.0% 
Absent Number of 
Persons 6 35 3 44 
 % within 
Clinical 
Features of 
Corpulmonale 
13.6% 79.5% 6.8% 100.0% 
 % within 
Severity of 
COPD 
100.0% 100.0% 33.3% 88.0% 
Total Number of 
Persons 6 35 9 50 
 
% within 
Clinical 
Features of 
Corpulmonale 
12.0% 70.0% 18.0% 100.0% 
% within 
Severity of 
COPD 
100.0% 100.0% 100.0% 100.0% 
  
 
68
 
‘p’ value is highly significant. All patients with corpulmonale had severe 
obstructive pattern.  66.7% of severe COPD patients developed corpulmonale.  
Table 9: PHT in COPD 
 
PHT Grade Frequency Percent 
No PHT 8 16.0 
Mild 27 54.0 
Moderate 13 26.0 
Severe 2 4.0 
Total 50 100.0 
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Our study reports that 84% of them have pulmonary hypertension. This is due to 
chronic hypoxia in COPD that may the reason for pulmonary hypertension.  Out of 
these 54% of them have mild, 26% moderate and 4% severe PHT. 
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Table 10: SMOKING INDEX AND PHT  
 
  
Smoking 
Index 
 
 
PHT Grade Total 
 
p value No 
PHT Mild Moderate Severe 
Non smoker Number of persons 5 9 0 1 15 
<0.001** 
 
 
% nonsmoker 33.3% 60.0% .0% 6.7% 100.0% 
% within PHT 
Grade 62.5% 33.3% .0% 50.0% 30.0% 
< 100 Number of persons 3 9 0 0 12 
 
 
% within Smoking 
Index 25.0% 75.0% .0% .0% 100.0% 
% within PHT 
Grade 37.5% 33.3% .0% .0% 24.0% 
101-300 Number of persons 0 9 9 1 19 
 
 
% within Smoking 
Index .0% 47.4% 47.4% 5.3% 100.0% 
% within PHT 
Grade .0% 33.3% 69.2% 50.0% 38.0% 
> 300 Number of persons 0 0 4 0 4 
 
 
% within Smoking 
Index .0% .0% 100.0% .0% 100.0% 
% within PHT 
Grade .0% .0% 30.8% .0% 8.0% 
Total 
Number of persons 8 27 13 2 50 
 
% within Smoking 
Index 16.0% 54.0% 26.0% 4.0% 100.0% 
% within PHT 
Grade 100.0% 100.0% 100.0% 100.0% 100.0% 
 
PHT severity is more in moderate and heavy smokers than mild smokers. ‘p’ value 
is highly significant. PHT severity found to be directly correlate with smoking 
index. 
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Table 11: DURATION OF SMOKING AND PHT 
 
  
Duration 
of 
Smoking 
in years  
 
 
PHT Grade 
Total 
 
p 
value 
No 
PHT Mild Moderate Severe 
Non 
smoker 
Number of persons 5 9 0 1 15  
 
 
 
 
 
 
 
 
 
.012* 
 %among nonsmokers 33.3% 60.0% .0% 6.7% 100.0% 
 % within PHT Grade 62.5% 33.3% .0% 50.0% 30.0% 
< 10 Number of persons 2 3 0 0 5 
 % within Duration of 
Smoking in years  40.0% 60.0% .0% .0% 100.0% 
 % within PHT Grade 25.0% 11.1% .0% .0% 10.0% 
11-20 Number of persons 1 8 3 1 13 
 % within Duration of 
Smoking in years  7.7% 61.5% 23.1% 7.7% 100.0% 
 % within PHT Grade 12.5% 29.6% 23.1% 50.0% 26.0% 
21-30 Number of persons 0 6 5 0 11 
 % within Duration of 
Smoking in years  .0% 54.5% 45.5% .0% 100.0% 
 % within PHT Grade .0% 22.2% 38.5% .0% 22.0% 
> 30 Number of persons 0 1 5 0 6 
 % within Duration of 
Smoking in years  .0% 16.7% 83.3% .0% 100.0% 
 % within PHT Grade .0% 3.7% 38.5% .0% 12.0% 
Total Number of persons 8 27 13 2 50  
% within Duration of 
Smoking in years  16.0% 54.0% 26.0% 4.0% 100.0% 
% within PHT Grade 100.0% 100.0% 100.0% 100.0% 100.0% 
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‘p’ value is significant. Duration of smoking is directly proportional to the PHT 
severity. Moderate PHT is present in those who are smoked more than 10 years. 
The percentage of moderate PHT is more in those who smoked more than 20 years. 
. 
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Table 12: SEVERITY OF COPD AND PHT GRADE 
  
 
 
‘p’ value is significant. Severity of COPD is directly related to severity of PHT. 
Severe PHT is associated with moderate and severe COPD patients. 
 
 
Severity 
of COPD 
 
 
PHT Grade 
Total 
 
p value No 
PHT Mild Moderate Severe 
Mild Number of persons 5 1 0 0 6 
 
 
 
 
 
 
<.001** 
 
% within Severity 
of COPD 83.3% 16.7% .0% .0% 100.0% 
% within PHT 
Grade 62.5% 3.7% .0% .0% 12.0% 
Moderate Number of persons 3 23 8 1 35 
 
% within Severity 
of COPD 8.6% 65.7% 22.9% 2.9% 100.0% 
% within PHT 
Grade 37.5% 85.2% 61.5% 50.0% 70.0% 
Severe Number of persons 0 3 5 1 9 
 
% within Severity 
of COPD .0% 33.3% 55.6% 11.1% 100.0% 
% within PHT 
Grade .0% 11.1% 38.5% 50.0% 18.0% 
Total 
Number of persons 8 27 13 2 50 
 
% within Severity 
of COPD 16.0% 54.0% 26.0% 4.0% 100.0% 
% within PHT 
Grade 100.0% 100.0% 100.0% 100.0% 100.0% 
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Table 13: SEVERITY OF COPD AND PHT GRADE IN CORPULMONALE 
 
All patients with corpulmonale have a severe obstructive pattern and 66.7% have 
moderate PHT. ‘p’value is significant. 
 
0
1
2
3
4
Severe
N
u
m
b
e
r 
o
f 
p
e
rs
o
n
s
Severity of COPD
Fig 13: Severity of COPD and PHT in Corpulmonale
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Severity 
of COPD 
 
 
PHT Grade 
Total 
 
p value No 
PHT Mild Moderate Severe 
Severe Number of persons  1 4 1 6 
 
0.002** 
 
% within Severity of 
COPD  16.7% 66.7% 16.7% 100.0% 
% within PHT Grade  100.0% 100.0% 100.0% 100.0% 
Total Number of persons  1 4 1 6 
 
 
% within Severity of 
COPD  16.7% 66.7% 16.7% 100.0% 
% within PHT Grade  100.0% 100.0% 100.0% 100.0% 
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Table1:14 DIASTOLIC DYSFUNCTION DISTRIBUTIONS 
 
Diastolic Function Frequency Percentage 
Normal 15 30.0 
Grade I 31 62.0 
Grade II 3 6.0 
Grade III 1 2.0 
Total 50 100.0 
 
 
70% of COPD patients have diastolic dysfunction in our study. 
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Table 15: SEVERITY OF COPD AND DIASTOLIC FUNCTION  
 
 
 
‘p’ value is highly significant. In grade1 diastolic dysfunction patients 71.4% have 
moderate obstruction and 19.4% have severe obstruction. In grade 2 diastolic 
dysfunction patients 100% have severe obstruction.COPD severity worsens the LV 
diastolic function. All mild COPD patients have normal LV diastolic function. 
Severity 
of COPD 
 
 
Diastolic Function 
Total 
 
p value 
Normal Grade I Grade II 
Grade 
III 
Mild Number of persons 6 0 0 0 6 
<0.001** 
 
% within Severity 
of COPD 100.0% .0% .0% .0% 100.0% 
% within Diastolic  
Dys Function 40.0% .0% .0% .0% 12.0% 
Moderate Number of persons 9 25 0 1 35 
 
% within Severity 
of COPD 25.7% 71.4% .0% 2.9% 100.0% 
% within Diastolic  
Dys Function 60.0% 80.6% .0% 100.0% 70.0% 
Severe Number of persons 0 6 3 0 9 
 
% within Severity 
of COPD .0% 66.7% 33.3% .0% 100.0% 
% within Diastolic  
Dys Function .0% 19.4% 100.0% .0% 18.0% 
Total 
Count 15 31 3 1 50 
 
% within Severity 
of COPD 30.0% 62.0% 6.0% 2.0% 100.0% 
% within Diastolic  
Dys Function 100.0% 100.0% 100.0% 100.0% 100.0% 
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Table 16: PHT AND DIASTOLIC FUNCTION 
 
‘p’ value is highly significant. All severe PHT patients have grade 2-3 diastolic 
dysfunction. 
 
PHT 
Grade 
 
 
Diastolic Function 
 
Total 
 
p value Normal Grade I Grade II 
Grade 
III 
No PHT Number of persons 7 1 0 0 8 
 
 
 
 
 
 
<0.001** 
 
%  No PHT  87.5% 12.5% .0% .0% 100.0% 
% within Diastolic  
Dys Function 46.7% 3.2% .0% .0% 16.0% 
Mild Number of persons 8 18 1 0 27 
 
% within PHT 
Grade 29.6% 66.7% 3.7% .0% 100.0% 
% within Diastolic  
Dys Function 53.3% 58.1% 33.3% .0% 54.0% 
Moderate Number of persons 0 12 1 0 13 
 
% within PHT 
Grade .0% 92.3% 7.7% .0% 100.0% 
% within Diastolic  
Dys Function .0% 38.7% 33.3% .0% 26.0% 
Severe Number of persons 0 0 1 1 2 
 
% within PHT 
Grade .0% .0% 50.0% 50.0% 100.0% 
% within Diastolic  
Dys Function .0% .0% 33.3% 100.0% 4.0% 
Total 
Number of persons 15 31 3 1 50 
 
% within PHT 
Grade 30.0% 62.0% 6.0% 2.0% 100.0% 
% within Diastolic  
Dys Function 100.0% 100.0% 100.0% 100.0% 100.0% 
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Table 17: PREVALENCE OF LV SYSTOLIC DYSFUNCTION 
 
Ejection Fraction (%) Frequency Percentage 
< 50 5 10.0 
> 50 45 90.0 
Total 50 100.0 
 
 
 
 
Our study reports that 10% of the COPD patients have LV systolic dysfunction 
(EF< 50%). Out of 50 cases 5 cases have EF <50%. 
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Table 18: SMOKING INDEX AND LV SYSTOLIC FUNCTION 
 
Smoking Index 
 
 
Ejection Fraction Total 
 
p value 
< 50 > 50 
Non smoker Number of persons 0 15 15 
<0.001** 
 
 
%Non- smoker .0% 100.0% 100.0% 
% within Ejection Fraction .0% 33.3% 30.0% 
< 100 Number of persons 0 12 12 
 
 
% within Smoking Index .0% 100.0% 100.0% 
% within Ejection Fraction .0% 26.7% 24.0% 
101-300 Number of persons 2 17 19 
 
 
% within Smoking Index 10.5% 89.5% 100.0% 
% within Ejection Fraction 40.0% 37.8% 38.0% 
> 300 Number of persons 3 1 4 
 
 
% within Smoking Index 75.0% 25.0% 100.0% 
% within Ejection Fraction 60.0% 2.2% 8.0% 
Total 
Number of persons 5 45 50 
 % within Smoking Index 10.0% 90.0% 100.0% 
% within Ejection Fraction 100.0% 100.0% 100.0% 
 
‘p’ value is highly significant. Moderate and heavy smokers have LVsystolic 
dysfunction. In moderate smokers 10.5% have LVEF<50%. But in heavy smokers 
75% have LVEF<50%.Smoking index is inversely related to the LV 
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systolicfunction. 
 
 
Patients more than 10 years of smoking have LV systolic dysfunction.  Patients 
who smokefor a long duration have higher rates of LV dysfunction.  
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Table 19:DURATION OF SMOKING AND LV SYSTOLIC FUNCTION 
 
 
Duration of 
Smoking in years 
 
 
Ejection Fraction 
 
Total 
 
p value 
< 50 > 50 
Non smoker Number of persons 0 15 15 
0.01* 
 
 
% Non-smoker .0% 100.0% 100.0% 
% within Ejection Fraction .0% 33.3% 30.0% 
< 10 Number of persons 0 5 5 
 
 
% within Duration of 
Smoking in years .0% 100.0% 100.0% 
% within Ejection Fraction .0% 11.1% 10.0% 
11-20 Number of persons 1 12 13 
 
 
% within Duration of 
Smoking in years 7.7% 92.3% 100.0% 
% within Ejection Fraction 20.0% 26.7% 26.0% 
21-30 Number of persons 2 9 11 
 
 
% within Duration of 
Smoking in years 18.2% 81.8% 100.0% 
% within Ejection Fraction 40.0% 20.0% 22.0% 
> 30 Number of persons 2 4 6 
 
 
% within Duration of 
Smoking in years 33.3% 66.7% 100.0% 
% within Ejection Fraction 40.0% 8.9% 12.0% 
Total 
Number of persons 5 45 50 
 
% within Duration of 
Smoking in years 10.0% 90.0% 100.0% 
% within Ejection Fraction 100.0% 100.0% 100.0% 
 
‘p’ value is significant. 33.3% of patients withmore than 30 years of smoking have 
LV systolic dysfunction. Duration of smoking is inversely related to the LV 
function. 
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Table20: SEVERITY OF COPD AND LV SYSTOLIC FUNCTION 
 
  
Severity of 
COPD 
 
 
Ejection 
Fraction 
 
Total 
 
p value 
< 50 > 50 
Mild Number of persons 0 6 6 
 
 
 
 
0.001** 
 
 
% within Severity of 
COPD .0% 100.0% 100.0% 
% within Ejection 
Fraction .0% 13.3% 12.0% 
Moderate Number of persons 1 34 35 
 
 
% within Severity of 
COPD 2.9% 97.1% 100.0% 
% within Ejection 
Fraction 20.0% 75.6% 70.0% 
Severe Number of persons 4 5 9 
 
 
% within Severity of 
COPD 44.4% 55.6% 100.0% 
% within Ejection 
Fraction 80.0% 11.1% 18.0% 
Total 
Number of persons 5 45 50 
 
% within Severity of 
COPD 10.0% 90.0% 100.0% 
% within Ejection 
Fraction 100.0% 100.0% 100.0% 
 
‘p’ value is highly significant. In moderate COPD patients only 2.9% of them have 
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 LVEF< 50%. But in severe COPD patients 44.4% of them have 
LVEF<50%.Among the LV systolic dysfunction patients 80% of them are severe 
obstructive pattern. Severity of COPD is inversely related to the LV systolic 
function 
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Table 21: PHT AND LV SYSTOLIC FUNCTION 
 
  
PHT Grade 
 
 
Ejection Fraction  
Total 
 
p value 
< 50 > 50 
No PHT Number of persons 0 8 8 
0.003** 
 
 
% No PHT  .0% 100.0% 100.0% 
% within Ejection Fraction .0% 17.8% 16.0% 
Mild Number of persons 0 27 27 
 
 
% within PHT Grade .0% 100.0% 100.0% 
% within Ejection Fraction .0% 60.0% 54.0% 
Moderate Number of persons 4 9 13 
 
 
% within PHT Grade 30.8% 69.2% 100.0% 
% within Ejection Fraction 80.0% 20.0% 26.0% 
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Severe Number of persons 1 1 2 
 
 
% within PHT Grade 50.0% 50.0% 100.0% 
% within Ejection Fraction 20.0% 2.2% 4.0% 
Total 
Number of persons 5 45 50 
 % within PHT Grade 10.0% 90.0% 100.0% 
% within Ejection Fraction 100.0% 100.0% 100.0% 
 
‘p’ value is highly significant. 
         Mild PHT patients have normal LV systolic function. Moderate and severe 
PHT patients have developed LV systolic dysfunction. In moderate PHT patients 
30.8% have LVEF <50%. But in severe PHT patients 50% have LVEF<50%. 
Severity of PHT is directly related to LV systolic dysfunction. 
 
Table 22: CORPULMONALE AND LV SYSTOLIC FUNCTION 
 
 
 
Clinical 
Features of 
Corpulmonale 
 
 
Ejection 
Fraction 
 
Total 
 
p value 
< 50 > 50 
Present Number of persons 3 3 6 
<0.001** 
 
% within Clinical Features 
of Corpulmonale 50.0% 50.0% 100.0% 
% within Ejection Fraction 60.0% 6.7% 12.0% 
Absent Number of persons 2 42 44 
 % within Clinical Features 4.5% 95.5% 100.0% 
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of Corpulmonale 
% within Ejection Fraction 40.0% 93.3% 88.0% 
Total 
Number of persons 5 45 50 
 
% within Clinical Features 
of Corpulmonale 10.0% 90.0% 100.0% 
% within Ejection Fraction 100.0% 100.0% 100.0% 
 
‘p’ value is significant. Among patients with clinical features of corpulmonale 50% 
of them have LVEF<50%.Inpatients without corpulmonale incidence LV systolic 
dysfunction is 4.5%. This report shows that presence of corpulmonale among 
COPD patients predicts worsening LV systolic function. 60% of the patients with 
LVEF<50% have the clinical features of corpulmonale. 
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DISCUSSION  
 COPD is now more prevalent in both developed and developing countries. It 
is a major health burden in the world. According to “WHO “report, COPD at 
present is the fourth commonest cause of death worldwide.(5) It is projected to be 
the third most common cause of death and fifth most common cause of chronic 
disability by the year 2030.In India half a million people die of COPD. (6)This is4 
times the mortality that it causes inUSA and Europe.(122) 
 In our study COPD is more prevalent in males and male to female ratio is 
4:1.This is mainly attributed to high prevalence of smoking among males.But 
according to WHO report thedisease affects men and women equally. In a large, 
multicentric study from India, the prevalence of COPD among general population 
was 4.1 per cent and the male to female ratio of 1.56:1.COPD is common in 
middle aged, so lower age limit of 40 is taken in our study. Most of the COPD 
patients are between 51 to 60 years of age.As age increases the disease prevalence 
also increases.This is attributed to age related decline in FEV1.Increasing 
prevalence with advancing age may reflect either cumulative exposure to smoking 
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and other risk factors or loss of elastic ity of lung tissue or both.National health 
interview surveyreport in United States in the year 2007 to 2009 shows the 
prevalence of COPD was higher in older age groups. 
 Swedish cohort study concluded that smoking was a causative risk factor of 
COPD with 76.2 percent attributed risk in a given population (27) where as in 
Denmark study it was 74.6 percent.(28)BTS guidelines reported that most COPD 
patients have history of at least 20 pack-year of smoking.[21Nonsmokers commonly 
have decline the rate FEV1 of about 30mL .Smokers on the other hand have a 
decline inFEV1 of about50 ml. Our study report shows increasing smoking index 
increases the prevalence and severity of COPD.   91.7% of mild smokers and 
84.2% of moderate smokers belong to moderate COPD. 75% heavy smokers have 
severe COPD. Our study patients have more than 10 years of smoking have 
moderate to severe obstruction. In more than 30 years of smoking history, 50% of 
them have severe obstruction.  
 Prevalence andseverity is more in low socio economic status. 76% of the 
COPD patients belongs to low socio economic status due to poor housing 
condition, overcrowding, poor environment, poor nutrition, alcohol, smoking and 
recurrent lower respiratory infections. 
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The development of pulmonary hypertension is a poor prognostic sign in 
patients with COPD, affecting both mortality and quality of life.Mild-to-moderate 
pulmonary hypertension is a common complication of COPD. Such a complication 
is associated with increased risks of exacerbation and decreased survival. 
Circumstantial and experimental evidence suggests that products of cigarette 
smoke can initiate pulmonary vascular changes in COPD. Our study reports that 
84% of them have pulmonary hypertension. In that 54% of them have mild, 26% 
moderate and 4% severe PHT. Severity of PHT is more in Moderate and heavy 
smokers than mild smokers. Duration of smoking is directly proportional to the 
severity of PHT. Those who are smoking more than 20 years the prevalence of 
moderate PHT is more. The severity of COPD is directly related to severity of 
PHT. Severe PHT is present in moderate and severe COPD patients. All 
corpulmonale patients have severe obstructive pattern and 66.7% of them have 
moderate pulmonary hypertension.Smoking index, duration of smoking and 
severity of COPD are positively correlated with severityof PHT.  
Chronic obstructive pulmonary disease patients have a high prevalence of 
left ventricular diastolic dysfunction, which is associated with disease 
severity. Boussuges et al found a high prevalence of left ventricular diastolic 
dysfunction in COPD patients relative to control subjects (76% vs. 35%)Rutten et 
al(123) and Funk et al also reported a prevalence >50%.(124,125) In our study reports 
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70% of our patients have diastolic dysfunction. In grade1 diastolic dysfunction 
patients 71.4% have moderate obstruction and 19.4% have severe obstruction. In 
grade 2 diastolic dysfunction patients 100% are severe obstruction. COPD 
severity worsens the LV diastolic function. All mild COPD have normal LV 
function. 
LV diastolic dysfunction shows progressive deterioration with increasing severity 
of PHT. All severe PHT patients have grade 2-3 diastolic dysfunction. 
 During the period from the first of May 2009 to end of December 2009a 
group studied theassessment of left ventricular systolic function (LVSF) at Ibn 
Sina Teaching Hospital wards and respiratory care unit among patients with 
COPD. The frequency of LVSD among COPD patients were 21.4% and the 
percentage of LVSD positive patients with pack years > 10 was 100%. These 
results confirm the association of pack years and mean duration of smoking with 
development ofLVSD(95).Our study reports that 10% of the COPD patients have 
LV systolic dysfunction. 75% of the heavy smokers and 33.3% of patients more 
than 30 years of smoking have LV systolic dysfunction. Smoking index and 
duration of smoking is directly associatedwith the development of LVSD.  
 A prospective study of 60 COPD patients with or without corpulmonale 
attending Manipal Teaching Hospital (MTH), Pokhara during 1st March, 2006 to 
28
th 
February, 2007 reported the prevalence of LV systolic dysfunction to be found 
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to be 26.7%. Severe cases 77% and moderate cases 14.2% had LV systolic 
dysfunction. The findings directly correlate with the severity of COPD i.e., more 
the severity of COPD more the probability for the incidence of LV systolic 
dysfunction.(126)In our study only 2.9% of moderate COPD patientsand 44.4% of 
severe COPD patients have LVEF<50%.Among patients with LV systolic 
dysfunction 80% showed severe obstructive pattern. Moderate and severe PHT 
patients have developed LV systolic dysfunction. In moderate PHT patients 30.8% 
have LVEF <50%. But in severe PHT patients 50% have LVEF<50%.In patients 
with corpulmonale 50% of them had LVEF<50%.This report shows that, severity 
of the COPD and PHT is inversely related tothe LV systolic function. A higher 
Smoking index, prolonged duration of smoking is associated with poor LV 
systolic function. Increasing severity of COPD is associated with worsening of 
LV systolic function.  
THERAPEUTIC IMPLICATION: 
Studiesreported that smokingplay an important role in the development of 
pulmonary vasculopathy; therefore,cessation smoking is avital part of treatment 
plan in patients with COPD. 
 Oxygen supplementation can modestly increase exercise tolerance, decrease 
PVR,PAP and improves the RV function. Long term oxygen therapy (LTOT) is   
slows and reverses partially the progression of PHT. 
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 Currently, long-acting beta2 adrenoreceptor agonistinhalation is preferred in 
most COPD patients because it is more quickly removed from myocardial and 
kidney receptors, thus making potentially deleterious cardiac effects less likely. 
 Cardiac arrythmias develops if the theophylline in serum levels exceeds 
20mg/L. Corticosteroids produce water retention. Hence, these drugs are best 
avoided in coexistent COPD-HF. 
 In COPD-HF, metabolic alkalosis occurs due to excessive diuresis that may 
inhibit ventilation is theoretically but in normal diuretic dosages pulmonary 
function is not affected. 
 A recent systematic analysis reported thatcardio selective beta-blocking 
agents can be safely administered to COPD patients(127). 
 ACE inhibitors and angiotensin-II antagonist are important for the treatment 
of HF.It decreases airways obstruction and also prevents the lunginjury. Other 
benefits are to improve the alveolar membrane gas exchange,decrease pulmonary 
inflammation and pulmonary vascular constriction. 
 Aldosterone can damage the alveolar-capillary membrane. Spironolactone 
has positive effects on gas diffusion. 
 Digitalis causes pulmonary vasoconstriction and thereforeis not usually 
recommended in COPD-HF. 
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  In COPD if heart failure is prominent, it may be good to introduce gradually 
specific beta 1 blocker like Metoprolol or Bisoprolol along with inhalational 
bronchodilator therapy after optimizing the heart failure therapy with drugs like 
diuretics,angiotensin converting enzyme inhibitor,angiotensin-IIantagonist and 
aldosterone antagonist. 
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CONCLUSION 
In our study chronic obstructive pulmonary disease is more common in 
males. Most patients belong to low socio economic status. COPD severity is 
directly proportional to smoking index and duration of smoking. Pulmonary 
hypertension severity is directly proportional to severity of COPD, smoking index 
and duration of smoking. 
 LV systolic dysfunction is directly proportional to severity of COPD. 
Smoking index and duration of smoking are positively correlated with 
development of LVSD. Our study reports that 44.4% of severe COPD patients 
have LVSD. So we recommendroutine echocardiography for all severe COPD 
patients.Smoking cessation should be avital part of treatment plan in COPD 
patients.COPD obscures the clinical signs of coexisting left ventricular dysfunction 
like cough, dyspnea, paroxysmal nocturnal dyspnea and orthopnea.Symptoms of 
dyspnea in COPD can be partially due to LV systolic and diastolic dysfunction. 
Early identification and treatment of LV dysfunction can improve the patient’s 
symptoms.Routine spirometry is used to diagnose and to assess the severity of 
COPD and echocardiography is mandatory to assess the cardiac status in COPD 
patients. 
InCOPD patients withLVSD, it may be good to introduce selective beta-1 
blocker, diuretics, ACE inhibitors,angiotensin-IIantagonist and aldosterone 
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antagonist. This treatment improves the LV function,reduces the recurrence 
ofCOPD exacerbation, improves the quality of life andreduces the morbidity and 
mortality. 
LIMITATIONS: 
1. The sample size is small because of the higher prevalence of patients belonging 
to the diseases mentioned in the exclusion criteria, in the Out/Inpatients population 
of the place of the study. A larger study in a higher center with more population 
will be able to predict the true prevalence of LV dysfunction in COPD patients. 
2. To rule out ischemic LV dysfunction patients would have required either non 
invasive nuclear imaging or invasive coronary angiogram. Since the investigations 
are not available in our hospital we have taken clinical and ECG criteria for CAD. 
3.Other rare causes for LV systolic dysfunction such as alcoholic cardiomyopathy 
are not considered. 
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ABBREVIATIONS 
COAD—Chronic Obstructive Airways Disease 
COPD – Chronic Obstructive Pulmonary Disease. 
GOLD –Global initiative for Obstructive Lung Disease 
WHO- World Health Organization. 
FEV1- Forced Expiratory volume in one second. 
FVC-Forced Vital Capacity. 
TNF alpha- Tumor Necrosis Factor alpha. 
IL-Interleukin. 
BTS-British Thoracic Society 
ATS-American Thoracic Society  
α1-AT-alpha 1-antitrypsin  
MMP-Matrix metalloproteinases 
BAL-bronchoalveolar lavage  
H2O2–Hydrogen peroxide 
MIP-macrophage inflammatoryprotein 
MCP- monocyte chemoattractant protein 
CRP-C-reactive protein  
TNF-tumour necrosis factor 
VEGF-vascular endothelial growth factor  
AHR-airway hyperresponsiveness 
RV -residual volume 
TLC -Total lung capacity  
PVR-Pulmonary vascular resistace 
RA- Right Atria 
RV-Right ventricle 
LV-Left ventricle 
HF-Heart failure 
MAT-Multifocal atrial tachycardia 
AF-Atrial fibrillation 
PAH-Pulmonary artery hypertension 
AVP-Arginine vasopressine 
ACE-Angiotensin converting enzyme 
ANP-Atrial naturitic peptide 
RVH-Right ventricular hypertrophy 
BMI-Body mass index 
TLCO-Transfer factor for carbon monoxide   
KCO- transfer coefficient  
PCWP-Pulmonary capillary wedge pressure 
BNP-Brain naturetic peptide 
LABA- long-acting beta2 agonist 
SABA-Shot-acting beta2 agonist 
PDE-phosphodiesterase 
ICS-inhaled corticosteroid  
LTOT-long-term oxygen therapy  
LAMA -long-acting muscarinic antagonist  
PFT-Pulmonary function test 
LVEF-Left ventricular ejection fraction 
IHD-Ishemic heart disease 
RBBB-Right bundle branch block 
LBBB-Left bundle branch block 
JVP-Jugular venous pressure 
PHT-Pulmonary hypertension 
PA-Pulmonary artery 
PVAT-PULMONARY VELOCITY ACCELERATION TIME 
LVSD-Left ventricular systolic dysfunction 
ECG- Electrocardiography. 
ECHO- Echocardiography 
RAD- Right Axis Deviation 
LAD- Left Axis Deviation 
NA-Normal axis 
TR- Tricuspid Regurgitation 
RTI-Respiratory tract infection 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
STUDY DETAIL  :  
STUDY CENTRE  :  
PATIENT’S NAME  : 
PATIENT’S AGE  : 
IDENTIFICATION NUMBER : 
 
I confirm that I have understood the purpose and procedure of the above study. I 
have the opportunity to ask questions and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However I understand that my 
identity would not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
Signature/thumb impression: 
Patient’s name and address:                                              
Place:                              Date: 
Signature of the investigator: 
Name of the investigator:                                        
Place:                              Date: 
  
PROFORMA 
 
NAME:       OP / IP No.:    
AGE& SEX:   
Occupation: 
ADDRESS:        
 
PRESENT HISTORY: 
 
PAST HISTORY: 
 
PERSONAL HISTORY: 
 
GENERAL EXAMINATION 
Pallor:    Icterus:    Cyanosis: 
Clubbing:    Lymphadenopathy:  Edema:  
JVP:  
Pulse Rate:    Blood Pressure:   SPO2: 
CVS:  
RS: 
P/A: 
CNS: 
INVESTIGATION 
1. CBC with ESR 
2. RBS 
3. Blood glucose –fasting / postprandial 
4. Lipid profile 
5. Blood Urea 
6. Blood Creatinine 
7. Liver function test  
8. Ultrasonagram Abdomen 
9. Chest X-ray 
 
10.ECG 
11.Pulmonary Function test 
 
12.Echocardiogram 
 
SIGNATURE OF INVESTIGATOR                SIGNATURE OF GUIDE 
DATE 
 

1 BABU 57 MALE 60 15                LOW             ABSENT 58% 65%          MODERATE          -          - NA          -          -          -                  MILD 1.5 110 44                  MILD Grade-1 63%
2 PITCHANDI 60 MALE 150 30                LOW             ABSENT 56% 62%          MODERATE         +          + RAD          +          +          -                TRIVAL 2.9 90 50           MODERATE Grade-1 65%
3 SUBRAMANI 67 MALE          -          -            MIDDLE             ABSENT 70% 66%          MODERATE          -          + RAD          -          -          -                 MILD 2.2 100 43                 MILD Grade-1 66%
4 MADHAVAN 63 MALE 200 40            MIDDLE             ABSENT 52% 60%          MODERATE          -          + RAD          -          -          -                 MILD 2.3 90 52           MODERATE Grade-1 56%
5 PARIMALA 60 FEMALE          -          -                LOW           PRESENT 40% 51%             SEVERE          +          + RAD          +          +         +            MODERATE 2.6 36 58              SEVERE Grade-2 55%
6 SANTHANAM 64 FEMALE          -          -                LOW             ABSENT 45% 55%             SEVERE          +          - RAD          -          +         +                MILD 2.3 100 35                 MILD Grade-2 63%
7 SUBBIAH 65 MALE          -          -            MIDDLE             ABSENT 72% 65%          MODERATE          -          - NA          -          -         -                    - 2 130          -                      - Grade-1 61%
8 KUMAR 50 MALE 400 30                LOW             ABSENT 35% 44%             SEVERE          +          + RAD          +          +         +            MODERATE 2.7 80 53           MODERATE Grade-1 31%
9 KOWSALYA 45 FEMALE          -          -            MIDDLE             ABSENT 60% 64%          MODERATE          -          - NA          -          -         -                 MILD 2.2 110 48                 MILD Grade-1 70%
10 KABALI 67 MALE 160 40                LOW             ABSENT 55% 63%          MODERATE          -          - NA          -          -         -                 MILD 1.9 100 33                 MILD Grade-1 59%
11 KUPPUSAMY 50 MALE 200 20                LOW           PRESENT 46% 54%             SEVERE         +         + RAD          -         +         -                     - 2.3 110         -                 MILD Grade-1 62%
12 SAKUNTHALA 80 FEMALE          -         -                LOW             ABSENT 56% 64%          MODERATE         -         - NA          -          -         -                 MILD 2.3 120 32                 MILD Grade-1 61%
13 GOPI 60 MALE 200 20                LOW             ABSENT 46% 52%          MODERATE        +         + RAD         +         +         +            MODERATE 30 56 50              SEVERE Grade-3 34%
14 SHANMUGAM 60 MALE 300 30                LOW             ABSENT 58% 66%          MODERATE        +         - RAD         -         +         -                MILD 2.3 100 31                 MILD Grade-1 64%
15 KUPPUSAMY 75 MALE 300 50                LOW           PRESENT 40% 54%             SEVERE        +         - RAD         +         +        +                MILD 2.8 80 56           MODERATE Grade-1 65%
16 KAMATCHI 50 FEMALE         -        -                LOW             ABSENT 39% 52%             SEVERE        -         - NA         -         -        -                MILD 2.2 100 43                 MILD Grade-1 67%
17 DEIVASIGAMANI 75 MALE 400 40                LOW             ABSENT 54% 62%          MODERATE        +         - RAD         -         +        -            MODERATE 2.6 80 52           MODERATE Grade-1 61%
18 IYYAPPAN 50 MALE 200 20                LOW             ABSENT 50% 61%          MODERATE        -         - NA         -         -        -                TRIVAL 2.2 106 32                  MILD NORMAL 65%
19 RANGANATHAN 55 MALE        -        -            MIDDLE             ABSENT 82% 69%                 MILD        -        - NA         -         -        -                    - 1.6 126        -                  -  NORMAL 68%
20 IYYAPPAN 47 MALE 40 10                LOW             ABSENT 83% 68%                 MILD        -        - NA         -         -        -                    - 1.7 130        -                    - NORMAL 67%
21 KANNAPPAN 55 MALE 75 25                LOW             ABSENT 56% 64%          MODERATE        -        - LAD         -         -        -                  MILD 2.5 90 38                 MILD NORMAL 61%
22 PERUMAL 56 MALE 280 28                LOW             ABSENT 58% 62%          MODERATE        +        - RAD         -         -        +                  MILD 2 110        -                 MILD NORMAL 60%
23 BABU 67 MALE 600 40                LOW           PRESENT 46% 55%             SEVERE        +        + RAD         +         +        +            MODERATE 2.7 73 54           MODERATE Grade-2 46%
24 ETHURAJ 57 MALE 150 15                LOW             ABSENT 62% 67%          MODERATE        +          + LAD         -         +        +            MODERATE 2.8 76 60           MODERATE Grade-1 63%
25 MOHAMEED 74 MALE 200 20                LOW             ABSENT 60% 64%          MODERATE        +        - NA         -         +        -            MODERATE 2.6 80 56           MODERATE Grade-1 55%
26 RANI 60 FEMALE         -          -                LOW             ABSENT 80% 67%                 MILD        -        - NA         -         -        -                    - 2.3 110         -                 MILD NORMAL 60%
27 KANNIAN 55 MALE 40 10                LOW             ABSENT 56% 61%          MODERATE        -        - NA         -         -        -                   - 1.8 130         -                    - NORMAL 64%
28 CHANDRAN 53 MALE 100 10                LOW             ABSENT 50% 58%          MODERATE        -        - LAD         -         -        -                   - 2.4 110 32                  MILD NORMAL 58%
29 KASINATHAN 63 MALE 200 20                LOW             ABSENT 56% 63%          MODERATE        -        - LAD         -         -         -                  MILD 2.6 100 52           MODERATE Grade-1 56%
30 ARUMUGAM 59 MALE         -          -            MIDDLE             ABSENT 66% 68%          MODERATE        -        - NA         -         -         -                TRIVAL 2.3 110 33                 MILD Grade-1 63%
31 RAJENDRAN 45 MALE         -          -            MIDDLE             ABSENT 80% 69%                 MILD        -        - NA         -         -         -                    - 1.8 130         -                    - NORMAL 66%
32 KURUVAMMAL 55 FEMALE         -          -                LOW             ABSENT 58% 64%          MODERATE        -        - NA         -         -         -                TRIVAL 2 110 34                  MILD Grade-1 55%
33 RAJAKANNU 44 MALE 100 10                LOW             ABSENT 54% 58%          MODERATE        +        - LAD         -         +         -                  MILD 2 116 32                  MILD NORMAL 63%
34 KUPPU 50 FEMALE        -         -                LOW             ABSENT 68% 66%          MODERATE        -        + NA         -         -         -                TRIVAL 2 110 33                  MILD NORMAL 64%
35 VELUSAMY 60 MALE 40 20            MIDDLE             ABSENT 56% 64%          MODERATE        -        - NA         -         -         -                    - 1.8 130         -                    - NORMAL 58%
36 SALIM 65 MALE 90 30            MIDDLE             ABSENT 55% 61%          MODERATE        +        - RAD         -         +         -                  MILD 2 110 34                  MILD Grade-1 60%
37 KRISHNAN 50 MALE 90 15                LOW             ABSENT 60% 66%          MODERATE        -        - NA         -         -         -                TRIVAL 2.1 110 33                  MILD Grade-1 63%
38 MOHAMEEDKASIM 74 MALE 100 20                LOW             ABSENT 55% 60%          MODERATE        -        - NA         -         -         -                TRIVAL 2.3 100 33                  MILD Grade-1 58%
39 MARRY 55 FEMALE        -         -            MIDDLE             ABSENT 82% 68%                 MILD        -        - NA         -         -         -                     - 1.8 130         -                     - NORMAL 65%
40 RAMASAMY 60 MALE 100 10            MIDDLE             ABSENT 65% 67%          MODERATE        -        - NA         -         -         -                TRIVAL 2 108 36                  MILD NORMAL 58%
41 NALLAN 65 MALE 300 30                LOW           PRESENT 42% 52%             SEVERE        +        + NA         +         +         +            MODERATE 2.8 73 52           MODERATE Grade-1 44%
42 ABDULKADHAR 70 MALE 150 20                LOW             ABSENT 65% 69%          MODERATE        -        - NA         -         -         -                TRIVAL 2 112 36                 MILD Grade-1 56%
43 RAMALAKSHMI 50 FEMALE        -         -                LOW             ABSENT 83% 67%               MILD        -        - NA         -         -         -                     - 2 130         -                     - NORMAL 64%
44 JAYAKUMAR 60 MALE 150 15                LOW             ABSENT 58% 60%          MODERATE        +        + RAD         -         +        +                  MILD 2.2 110 38                 MILD Grade-1 58%
45 KANNAN 55 MALE 100 20                LOW             ABSENT 60% 64%          MODERATE        -        - LAD         -         -        -                TRIVAL 2.2 104 33                  MILD Grade-1 57%
46 MURUGAN 65 MALE 120 30            MIDDLE             ABSENT 56% 60%          MODERATE        -        - LAD         -         -        -                TRIVAL 1.9 112 34                  MILD Grade-1 64%
47 KASIM 58 MALE 200 30                LOW             ABSENT 58% 64%          MODERATE       +        - NA         -        +        +                  MILD 2.6 90 53           MODERATE Grade-1 55%
48 MEYYAPPAN 65 MALE 120 30                LOW             ABSENT 55% 62%          MODERATE        -        - NA         -         -        +                  MILD 2.3 110 33                  MILD Grade-1 62%
49 ANTONY 70 MALE 350 35                LOW           PRESENT 44% 52%             SEVERE        +        + RAD         +        +        +            MODERATE 2.7 83 56           MODERATE Grade-1 48%
50 SANKARAN 60 MALE 250 30                LOW             ABSENT 60% 66%          MODERATE        -        + NA         -        -        +                  MILD 2.9 94 60           MODERATE Grade-1 58%
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